ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Ends Polyphor Antibiotics Pact

by Lisa M. Jarvis
December 7, 2015 | APPEARED IN VOLUME 93, ISSUE 48

Roche has dissolved an antibiotics pact with the Swiss biotech firm Polyphor. The companies joined forces in 2013 to develop POL7080, a macrocycle antibiotic currently in Phase II tests to treat hospital-acquired bacterial infections caused by Pseudomonas aeruginosa. Polyphor says it plans to continue the trials. The partnership was one of the first established by Roche as it reentered the antibiotics field; it has since sealed partnerships with Meiji Seika Pharma, Discuva, and Spero Therapeutics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment